Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19

 Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19

Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19

Shots:

  • The collaboration supports the development of vaccines leveraging Heat’s gp96 platform designed to target SARS-CoV-2 coronavirus causing COVID-19
  • Heat’s subsidiary Zolovax will focus on the development of COVID-19 vaccines while the University of Miami will develop and test vaccines utilizing Heat’s gp-96 backbone, expressing antigens associated with COVID-19
  • Heat’s gp96-based therapeutic platform reprograms live cells to continually secrete antigens of interest bound to the gp96, thus activating a robust T-cell response against antigens

Click here ­to­ read full press release/ article | Ref: Heat Biologics | Image:  Insider Financials

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post